Adicet Bio Inc. (ACET)
NASDAQ: ACET
· Real-Time Price · USD
0.83
-0.01 (-1.05%)
At close: Sep 26, 2025, 10:58 AM
-1.05% (1D)
| Bid | 0.82 |
| Market Cap | 68.88M |
| Revenue (ttm) | 6.51M |
| Net Income (ttm) | -118.64M |
| EPS (ttm) | -1.28 |
| PE Ratio (ttm) | -0.65 |
| Forward PE | -0.81 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 0.83 |
| Volume | 114,358 |
| Avg. Volume (20D) | 487,225 |
| Open | 0.83 |
| Previous Close | 0.84 |
| Day's Range | 0.81 - 0.84 |
| 52-Week Range | 0.45 - 1.54 |
| Beta | 1.61 |
| Ex-Dividend Date | n/a |
About ACET
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ACET
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ACET stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts4 months ago
-18.65%
Adicet Bio shares are tracing lower. The company r...
Unlock content with
Pro Subscription
7 months ago
+9.79%
Adicet Bio shares are trading higher after the company was granted FDA Fast Track designation to ADI-001 for treating refractory systemic lupus erythematosus with extrarenal involvement.
4 weeks ago · businesswire.com
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...
